Institut Curie, PSL Research University, INSERM, U900, Saint Cloud, France.
Conservatoire National des Arts et Métiers, Paris, France.
JCO Precis Oncol. 2021 Nov;5:173-176. doi: 10.1200/PO.20.00164.
Immunotherapy has been approved to treat many tumor types. However, one characteristic of this therapeutic class is that survival benefit is due to late immune response, which leads to a delayed treatment effect. Quantifying the benefit, if any, of such treatment, will thus require other metrics than the usual hazard ratio and different approaches have been proposed to quantify the long-term response of immunotherapy.
In this paper, we suggest to use quantile regression for survival data to quantify the long-term benefit of immunotherapy. Our motivation is that this approach is not trial-specific and provides clinically understandable results without specifying arbitrary time points or the necessity to reach median survival, as is the case with other methods. We use reconstructed data from published Kaplan-Meier curves to illustrate our method.
On average, patients from the immunotherapy group have 60% chance to survive 5.46 months (95% CI, 2.57 to 9.02) more than patients in the chemotherapy group.
免疫疗法已被批准用于治疗多种肿瘤类型。然而，此类治疗药物的一个特点是，生存获益是由于晚期免疫反应，这导致治疗效果延迟。因此，要量化此类治疗的任何益处，都需要采用通常的风险比以外的其他指标，并且已经提出了不同的方法来量化免疫疗法的长期反应。
在本文中，我们建议使用生存数据的分位数回归来量化免疫疗法的长期获益。我们的动机是，这种方法不是特定于试验的，并且提供了临床上可理解的结果，而无需指定任意时间点或达到中位生存时间，这是其他方法的情况。我们使用来自已发表的 Kaplan-Meier 曲线的重建数据来说明我们的方法。
平均而言，与化疗组相比，免疫治疗组的患者有 60%的机会多存活 5.46 个月（95%CI，2.57 至 9.02）。
